How semaglutide works for weight loss — and what it actually does in your body

The biggest myth: semaglutide suppresses appetite the way willpower does

Most people who ask how semaglutide works assume it does something similar to a strong cup of coffee or a motivational boost, that it somehow makes you more disciplined around food. That is not what happens. Semaglutide acts on receptors in the brain's hypothalamus, the region that governs hunger and satiety, and sends signals that would normally arrive only after a meal. The result is that you feel full earlier, stay full longer, and find yourself thinking about food less often. None of that is a matter of effort. The appetite reduction is physiological.

This distinction matters because it reframes what success looks like on treatment. People are not resisting cravings through gritted teeth, they often describe simply not feeling hungry in the way they used to. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks and found that those taking semaglutide 2.4 mg alongside lifestyle support lost an average of around 15% of their starting body weight. That is not a supplement-level effect. It reflects a meaningful change in appetite biology.

The second thing semaglutide does is slow gastric emptying, the rate at which food moves from the stomach into the small intestine. Food sits in the stomach longer, which extends the physical sensation of fullness after a meal. Between the brain signals and the slowed digestion, appetite and portion size both fall, and they fall in a way that is largely automatic rather than effortful. Understanding what drives these changes in detail helps set realistic expectations for treatment.

What GLP-1 actually is, and why the body already makes it

GLP-1 stands for glucagon-like peptide-1, a hormone released naturally by the small intestine when food is eaten. Its job is to tell the pancreas to release insulin, tell the brain that nutrients have arrived, and put the brakes on appetite. In many people with obesity, GLP-1 signalling is blunted or brief, the hormone degrades quickly in the bloodstream, so its effects are short-lived.

Semaglutide is a synthetic analogue of GLP-1, engineered to be structurally similar but far more stable. Where natural GLP-1 has a half-life of a couple of minutes, semaglutide lasts long enough in the body to be dosed just once a week. It binds to the same receptors, produces the same appetite and satiety signals, but sustains them across seven days. The mechanism that makes Wegovy effective is really the body's own hunger-regulating system, extended and amplified.

It is worth knowing that semaglutide also appears to influence reward pathways linked to food. Some people on treatment report less interest in highly palatable foods specifically, not just a general reduction in hunger. The research into this aspect is ongoing, but it aligns with what prescribers hear from patients in practice. More on semaglutide as a medicine covers the broader clinical picture.

How Wegovy's dosing schedule reflects the way semaglutide works

Because semaglutide works by engaging receptors in the gut and brain, starting at too high a dose produces strong side effects, nausea, vomiting, and indigestion are the most common. The licensed dosing schedule for Wegovy addresses this directly. Treatment begins at 0.25 mg weekly, a level chosen specifically to let the body adjust, then steps up through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose. Each step takes around four weeks, and the pace is set by the prescriber based on how the individual is tolerating treatment.

In April 2026, the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, following trials that reported around 20.7% average weight loss over 72 weeks, announced by the MHRA on 14 April 2026. That pen is licensed for adults with a BMI of 30 or above; the titration schedule still begins at 0.25 mg and steps up to 7.2 mg as the maximum. Specific dose availability is always confirmed at consultation, because what reaches patients at any given moment depends on the supply chain.

Side effects are most noticeable at the beginning of treatment and after each dose step, and they tend to settle over a week or two. Eating smaller meals, staying hydrated, and avoiding rich or fatty food early on makes a practical difference. Anyone who experiences severe, persistent stomach pain that spreads to the back should seek urgent medical attention, as this can be a sign of pancreatitis. The full overview of weight-loss treatments covers when to discuss symptoms with a clinician.

Who semaglutide for weight loss is licensed for, and where it sits in the UK

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability, the prescriber reviews the full clinical picture, including any contraindications.

On the NHS, Wegovy is available through specialist weight management services under NICE guidance (TA875), and waiting lists can be long. Private treatment through a regulated pharmacy is an alternative for people who do not meet NHS criteria or would prefer not to wait. If cost is a factor, understanding what private Wegovy typically costs in the UK is a useful starting point before committing to any provider. For context on how semaglutide compares to the dual-agonist approach of tirzepatide, the detailed Wegovy mechanism page draws that comparison clearly.

Wegovy is not suitable during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for anyone under 18. A prescriber will go through all of this at assessment, the free consultation at nume is the place to check your eligibility with a GPhC-registered Independent Prescriber, reviewed the same day.